| | | |  | | | | By Jason Mast Wellcome Collection Despite good results, TIL therapy, which uses T cells that infiltrated tumors, has not been approved. This time, Dutch regulators may bite. Read More | | By Adam Feuerstein Andy Wong/AP Still, the new data show lung cancer patients are not benefiting from Lumakras as much as previously hoped. Read More | | By Sarah Owermohle White House photo Wegrzyn currently works at Boston-based Ginkgo Bioworks but has experience in two government agencies Biden hopes to emulate with ARPA-H. Read More | | Sponsor content by Merck Fighting cancer requires an open mind Immunotherapies have ushered in a new era of cancer treatment, but there are still patients who do not respond to available therapies, or their cancer progresses. That's why Merck scientists are exploring over 20 novel mechanisms and different modalities to advance new treatment options for patients. Learn more. | | By Adam Feuerstein Yichuan Cao/Sipa USA The result could lead to a better treatment option for patients with advanced breast cancer and strengthen the drug’s commercial outlook. Read More | | By Damian Garde Good Therapeutics The deal marks an encouraging sign in what remains a difficult market for biotech startups, which have struggled to maintain their valuations. Read More | | By Matthew Herper Molly Ferguson for STAT At the start, there was a kind of “heads you lose, tails I win” kind of logic about Illumina’s decision to close the Grail purchase. Read More | | By H. Gilbert Welch Gillian Flaccus/AP Until a trial shows that a liquid biopsy to detect early cancer helps more than it harms, Medicare should not be compelled to pay for it. Read More | | By Matthew Herper Wikimedia Commons Relay’s drug, known as RLY-4008, works only in tumors that have a particular kind of mutation related to a gene for a protein called FGFR2. Read More | |
No comments